Objective: To investigate the utility of multiphase computed tomography (CT) and percutaneous renal mass biopsy (PRMB) in differentiating between papillary renal cell carcinoma (pRCC)-Type 1 and -Type 2, as emerging data have suggested differential enhancement patterns in different renal tumor histologies.
Introduction
An increasing number of individuals are diagnosed with renal cell carcinoma (RCC) each year, with more cancers diagnosed at earlier stages. [1, 2] Papillary RCC (pRCC) is the second most frequent RCC subtype, accounting for approximately 13%-15% of all known RCC lesions. [3] In comparison with clear cell RCC (ccRCC), at presentation pRCC has a hypovascular appearance, and tends to have smaller tumor size of lower stage, though it may also have worse prognosis in the setting of metastatic disease. [4] Delahunt and Eble further defined pRCC into two subtypes, Type 1 and Type 2, on the basis of histology. [5] These two subtypes show different clinicopathologic behaviors with pRCC-Type 2 generally having worse prognosis than pRCC-Type 1. [6] Knowledge of the differential biological potential of different papillary subtypes may therefore impact follow-up strategy after de- finitive treatment, and also potentially influenced the decision to offer definitive management as opposed to active surveillance. [7] Computed tomography (CT) is currently the reference standard method for identification and clinical staging of renal masses. [1, 2] However, preoperative pathological risk in a substantial number of patients with localized renal masses identified on CT who undergo surgery has been inaccurately or incompletely predicted. [8] Few radiologic studies have evaluated the differences between pRCC-Type 1-and pRCC-Type 2, and the issue of differentiation between two subtypes remains unresolved. [9] While current guidelines of American Urological Association and European Association of Urology recommend percutaneous renal mass biopsy (PRMB) as part of ablative protocol and for consideration in active surveillance, [1, 2] PRMB has gained increasing impetus as a first line-management option to delineate tumor histology and to inform therapeutic strategy, with emerging reports suggesting high accuracy and low morbidity and oncologic risk. [7, 10] We sought to investigate imaging characteristics of pRCC-Type 1 and Type 2 tumors, and examine utility of multiphasic CT and PRMB in distinguishing between the two subtypes in a cohort of patients with pRCC who underwent extirpative surgery.
Material and methods

Study patients
Institutional Ethics Review Board approved retrospective analysis of pRCC patients who underwent multiphase CT prior to surgical extirpation from July 2011 to April 2016. Fifty-one patients with pathologically confirmed pRCC whose pathological specimens were confirmed by one of two dedicated uropathologists (AS, DEH) were ultimately analyzed. Our cortical renal neoplasm workup, imaging evaluation and follow-up had been described previously. [11] Briefly, multiphasic CT were obtained as part of a work up for renal tumors suspicious for malignancy prior to management. Patients were counseled as to management options [Radical nephrectomy (RN), partial nephrectomy (PN), ablation, active surveillance (AS)] based on tumor size/ stage, and patient baseline performance status and co-morbidities.
Patients who ultimately underwent RN or PN were included in this analysis. In this context patients were offered PRMB in the context of prior history of malignancy, or for risk stratification prior to therapeutic choice. Patients who opted for ablation or AS were not included in the analysis, and neoplasms not diagnosed by renal mass protocol CT and without confirmed pRCC diagnosis were excluded from analysis.
CT imaging evaluation
CT was performed with 64-detector row helical scanners (GE Medical Systems, Milwaukee, WI, USA). CT images were acquired with following parameters: 120 kVp, 200 mA-600 mA depending on size of the patient. Pitch varied from 0.75-1.5. Section thickness measured 0.625 mm reconstructed at 5 mm. Patients were scanned using renal mass protocol that included 4 phases: non-contrast, corticomedullary (35 sec delay), nephrographic (80 sec delay), and a delayed (180 sec) phases. All patients received 140cc of nonionic intravenous (IV) contrast material (Iohexol 350, Omnipaque; GE Healthcare, Milwaukee, WI, USA) at a rate of 4 mL/sec. Images were reviewed on a picture archiving and communication system workstation. Two radiologists (LA, FH) were blinded to tumor histology while interpreting imaging. When there was discordance in image interpretation, final decision was reached by consensus.
PRMB protocol and histologic evaluation
Our PRMB technique had been described previously. [12] All PRMB were performed by an interventional radiologist (G R-S) under CT guidance, utilizing 16-or 18-gauge needle and obtaining 2 cores. Uropathologists (VD, AS, DEH) were blinded to the clinical information/CT findings when they reviewed slides and classified biopsies and tumor specimens into pathologic subtypes of pRCC. In case of disagreement in interpretation, final decision was reached by consensus. Pathologic tumor stage (pT) and grade were recorded according to TNM and WHO classifications. [13, 14] 
Image analysis
The following parametres were interpreted: tumor size (maximal diameter, cm), categorical measurements of heterogeneous or homogeneous composition, well-or ill-defined borders, involvement of collecting system, presence of calcifications, necrosis, cystic components, and associated findings (lymphadenopathy or venous thrombus), and attenuation values [Hounsfield Units, (HU)]. [11] Attenuation measurements were carried out by determination, and placement of region of interest (ROI) over the area with the highest attenuation detected during corticomedullary and/or nephrographic phase(s). Matching ROI were placed in the same location on non-contrast and delayed phases. ROI covered maximal measurable area that demonstrated highest enhancement. If the mass enhanced homogeneously, ROI covered one-half to two-thirds of the mass. Cystic, calcified, or necrotic areas were not included in ROI determination. [11] Statistical analysis Data concerning clinical, and demographic (age, sex, race, body mass index, history of smoking) characteristics and clinical/surgical/pathological tumor characteristics [tumor size (cm), type of surgery (radical/partial nephrectomy), and tumor grade (I/II vs. III/IV)], imaging characteristics (mass borders, composition, collecting system involvement, calcification, necrosis, cystic component, lymphadenopathy, or venous thrombus), and attenuation measurements [Hounsfield Units (HU), for noncontrast (NC), corticomedullary (CM), nephrographic (N) and delayed (D) Phases] were collected.
Data were comparatively analyzed between pRCC subtypes. Among clinicopathological characteristics, categorical variables were compared using Fisher's exact or Pearson's chi-square test for, Student's t-test for normally, and Mann-Whitney U test for non-normally distributed continuous variables. Absolute enhancement (HU) washout value for the mass was calculated by the formula (nephrographic-delayed)/(nephrographic-non contrast) and reported as a raw value. [15] Previously reported data using an absolute washout value <0 was highly specific for pRCC and therefore this value was also used as a threshold for comparison within pRCC subtypes. [11] Subgroup analysis of patients who underwent PRMB prior to surgical resection was also carried out for overall accuracy of histopathological evaluation of biopsy material in predicting final tumor histology and grade (high vs. low-grade). Statistical analysis was performed with IBM Statistical Package for the Social Sciences version 17.0 (IBM SPSS Statistics; Armonk, NY, USA). P value <0.05 was defined as significant.
Results
Fifty-one patients met inclusion criteria (23 pRCC-Type 1, 28 pRCC-Type 2). Table 1 demonstrates demographics and clinical characteristics of the patients There was no difference noted with respect to demographic parameters, median clinical tumor size (pRCC-Type 1 2.8 cm vs. pRCC-Type 2 2.6 cm, p=0.832) and distribution of pathological stage (p=0.651). Nonetheless, pRCC-Type 2 had significantly higher proportion of high-grade (III/IV) tumors (42.9% vs. 8.7%, p=0.011). Imaging characteristics are demonstrated in Table 2 . There were no differences between pRCC-Type 1-and pRCC-Type 2 with respect to irregular borders (5.6% vs. 14.3%, p=0.677), necrosis (13.0% vs. 28.6%, p=0.247), calcifications (p=1.000), collecting system involvement [abuts, displaces, effaces (p=1.000)], heterogeneous vs. homogenous enhancement on imaging (p=0.510), or presence of associated findings (lymphadenopathy, p=0.617; venous thrombus, p=0.242; Figure 1 ).
Attenuation measurements for different phases and washout calculations are demonstrated in 
Discussion
We present the largest scale comparative study between pRCCType 1 and Type 2 tumors which examied imaging characteristics of these types on CT scan and the first to analyze utility of PRMB. While earlier reports have demonstrated that pRCC may have a distinct appearance from ccRCC and other renal cortical tumor histologies, [10, 15] our findings suggest that multiphasic CT does not distinguish between pRCC subtypes, and that PRMB can accurately distinguish between these histological variants, and may have utility in patients in whom accuracy of risk stratification is sought prior to definitive management.
Our data suggest that pRCC-Type 1-and Type 2 tumors have substantial overlap in key CT findings including tumor size, definition of borders, heterogeneity, collection system involvement, presence of calcifications, and necrosis, enhancement pattern and values and washout. Our findings are in contrast to those of Yamada et al. [9] , who conducted a retrospective analysis of 12 pRCC-Type 1 and 8 pRCC-Type 2 tumors, and noted that pRCC-Type 1 tumors had more distinct margins whereas pRCCType 2 showed more indistinct margins, infiltrative growth pattern, and increased heterogeneity. Unlike our cohort, the tumors in their series were not well-matched for size, with a median size of 3.3 cm for Type 1 vs. 5.1cm for pRCC-Type 2 (p=0.037). Herts et al. [15] compared triphasic CT enhancement patterns in 90 patients and found that pRCC is more likely to be homogeneous in comparison with other renal cell carcinomas (p=0.001), although size was not accounted for in this study. Conversely, when comparing RCC enhancement patterns on CT and controlling for tumor size, Kim et al. [16] found that both pRCC and ccRCC tumors larger than 3 cm were predominantly heterogeneous with areas of necrosis. Thus, Yamada et al. [9] findings may be attributed more to tumor size and histology.
CT washout formula is commonly used to evaluate the enhancement patterns of adrenal masses [17] and has been previously found by our group and others to differentiate ccRCC from nonccRCC, with a washout value <0 being 100% specific for nonccRCC. [11, 18] When using the CT enhancement washout formula in our current analysis, we found no difference in washout values between the two pRCC subtypes, which further substantiates our findings that while CT may be specific in determining non-ccRCC histology, it may not be a reliable imaging modality to distinguish between pRCC subtypes.
Similar findings have been observed in differentiation between pRCC and ccRCC tumors but magnetic resonance imaging (MRI) could not distinguish between pRCC subtypes. [19] [20] [21] [22] Oliva et al. [19] compared contrast-enhanced MRI tumor signal intensity (SI) ratios (tumor SI/renal cortex SI) of 21 pRCC and 16 ccRCC lesions and found that tumor SI ratios on T1-weighted images were similar for the two RCC subtypes, although on T2-weighted images pRCC had a significantly lower SI ratio compared to ccRCC tumors (p<0.01). On qualitative assessment authors reported T2-weighted hypointense (SI≤0.66) tumors had a specificity of nearly 100% for pRCC, whereas SI of a hyperintense tumor was 100% specific for cRCC. Similarly, Young et al. [20] conducted a study to investigate the performance of contrast enhancement on multiphasic MRI to differentiate ccRCC from other RCC subtypes and reported that relative corticomedullary signal intensity differentiated ccRCCs from other RCC subtypes with an AUC of 0.93 and 90% accuracy, 90% sensitivity, and 90% specificity. Additionally, Vargas et al. [21] compared change in MRI SI between pre-contrast and post-contrast phases, and demonstrated that pRCC had significantly less enhancement than ccRCC in all three post-contrast phases (p<0.000-0.012). However, similar to CT findings, MRI imaging characteristics of Type I-and Type II-pRCC demonstrated substantial overlap. When comparing contrast enhanced MRI characteristics of 15 pRCC-Type 1 and 6 Type II-pRCC-Type 2 tumors, Egbert et al. [22] revealed no difference in definition of margins, presence of necrosis, lymphadenopathy, or signal intensity on T1-, and T2-weighted images between subtypes, and, therefore, concluded that pRCC subtype classification is likely not possible using MRI.
Although our pRCC subtype groups had a similar median tumor size and stage distribution, we found a significantly proportion of higher grade (3/4) tumors in the pRCC-Type 2 group (42.9% vs. 8.7%, p=0.011), which is consistent with previous reports. [4, 9] Given what we know about identified differences in biological potentials of different histologic subtypes of pRCC, [3] [4] [5] [6] and the limitations in differentiating between subtypes by either CT or MRI, it is not enough to declare a small non-ccRCC appearing renal mass safe for surveillance. Thus, in a patient where consideration is being given for active surveillance versus treatment, and where presence of aggressive histological features may spur definitive management, PRMB may be useful to stratify oncologic risk, whether imaging findings are suggestive or not of ccRCC.
Halverson et al. [23] assessed accuracy of a biopsy-directed treatment algorithm in correctly assigning AS vs. treatment in patients with small renal masses, in a retrospective analysis of 151 patients with cT1a renal masses who underwent biopsy and subsequent surgical excision. Overall agreement between biopsy and final pathology was 92%. When analyzing for pRCC, 25 patients were noted to have pRCC as detected by preoperative histopathological examination of biopsy materials, while 27 patients had pRCC on final histopathological examination with an overall diagnostic accuracy of 93%. When categorized by histological subtype, pRCC-Type 1 diagnoses were made based on 10 preoperative biopsy materials, and 16 on final pathology (diagnostic accuracy, 62.5%). Histopathological examination of preoperative biopsy materials predicted diagnosis of pRCCType 2 in 4 patients compared to diagnosis of pRCC-Type 2 in 5 patients based on final pathology (diagnostic accuracy of 80%). Furthermore, preoperative histopathological examination of biopsy materials predicted 10/12 (83.3%) grade 1/2 pRCCType 1. The authors in their analysis included papillary RCC not otherwise specified in 11 preoperative and 6 postoperative specimens. The authors' findings suggest a high degree of accuracy in predicting pRCC histology overall, pRCC-Type 2 histology, and distinguishing between low-, and high-grade pRCC-Type 1 histology. While conduction of larger -scale studies with greater number of case series is necessary so as to correlate preoperative biopsy, imaging and final pathology findings. Findings of Halverson et al. [23] are similar to our findings and suggest that PRMB may be an effective and accurate predictor of papillary subtype and grade, accurately reflect oncologic risk and thus contribute to risk stratification.
Our study is limited by its retrospective design and inherent selection bias towards treatment for patients who were perceived to have appropriate risk from a medical and surgical standpoint. Furthermore, we excluded patients with non-pRCC pathology, and focused only on multiphasic CT findings. Indeed, while our analysis is limited by numbers and potential applicability, it stands as the largest comparison in imaging and pathological characteristics between the two subtypes of pRCC, and is unique in being well-matched in terms of tumor size. Given that our analysis is limited to those patients with pre-existing imaging and pathology results, our ability to test true utility of these imaging parameters for diagnosis was inherently limited, and prospective investigation is a requisite.
In conclusion, in this well-matched cohort study with respect to tumor size and stage, there was substantial overlap of key radiographic findings, despite pRCC-Type 2 having greater proportion of high-grade tumors. While multiphase CT scan was not able to differentiate between pRCC subtypes, in patients where PRMB was obtained, accurate histologic diagnosis was made in >90% of the patients. While further investigation is a requisite, in patients with imaging criteria suggestive of non-clear cell RCC in which further diagnostic refinement is sought, PRMB may add further risk stratification information that multiphasic CT scan is not able to achieve.
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